South Korean biopharmaceutical firm Celltrion Inc. said Friday that it has inked a deal with its affiliate to sell two biosimilars –Truxmia and Herzuma.
Under the deal, worth 151.4 billion won (US$136.4 million) and equivalent to 15.95 percent of the company`s annual sales, Celltrion will sell the biosimilars to Celltrion Healthcare, which handles Celltrion`s overseas business.
Truxima, which references Roche`s MabThera, also known as Rituxan, is used in the treatment of a number of diseases, including rheumatoid arthritis and non-Hodgkin`s lymphoma, a type of leukemia.
Herzuma, a drug based on Herceptin — originally developed by Swiss pharmaceutical giant Roche Holding — is a drug to treat breast cancer.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.